摘要
膀胱过度活动症（overacfjvebladderOAB）的发病机制目前尚不十分明确，本文主要从相关离子通道、尿路上皮、间质细胞方面探讨OAB的分子机制。
出处
《国际泌尿系统杂志》
2012年第1期87-90,共4页
International Journal of Urology and Nephrology
参考文献28
-
1Yoshida M,Masunaga K,Nagata T. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction:pathophysiology and pharmacotherapy of overactive bladder[J].Journal of Pharmaceutical Sciences,2010,(02):128-134.
-
2En Meng MD. Ph D.Resent research advance in the pathophysiology of overactive bladder[J].Incont Pelvic Floor Dysfunct,2009,(Suppl 1):5-7.
-
3Frazier EP,Peters SL,Braverman AS. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors[J].Naunyn-Schmiedeberg's Archives of Pharmacology,2008,(4-6):449-462.doi:10.1007/s00210-007-0208-0.
-
4Schneider T,Hein P,Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder.I. Phospholipases and Ca2 + sources[J].Journal of Pharmacology and Experimental Therapeutics,2004,(01):47-53.
-
5Schneider T,Fetscher C,Krege S. Signal transduction underlying carbachol-induced contraction of human urinary bladder[J].Journal of Pharmacology and Experimental Therapeutics,2004,(03):1148-1153.
-
6Wegener JW,Schulla V,Lee TS. An essential role of Cavl,2 L-type calcium channel for urinary bladder function[J].Federation of America Societies for Experimental Biology Journal,2004,(10):1159-1161.
-
7Wibberley A,Chen Z,Hu E. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle[J].British Journal of Pharmacology,2003,(05):757-766.
-
8Rajasekaran M,Wilkes N,Kuntz S. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats[J].Neurourology and Urodynamics,2005,(3):295-300.doi:10.1002/nau.20122.
-
9Morelli A,Squecco R,Failli P. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder[J].American Journal of Physiology-Cell Physiology,2008,(05):C1206-C1214.doi:10.1152/ajpcell.90634.2007.
-
10Ferro A. beta-adrenoceptors and potassium channels[J].Naunyn-Schmiedeberg's Archives of Pharmacology,2006,(03):183-185.doi:10.1007/s00210-006-0065-2.
同被引文献39
-
1赵军,贺大林,刘润明,王明珠,王小宁,邢俊平,南勋义.良性前列腺增生相关的膀胱痉挛病因分析及治疗[J].中华男科学杂志,2005,11(4):275-277. 被引量：44
-
2Fantl J A,Wyman J F, Mcclish D K, et al. Efficacy of bladder training in old women with urinary incontinence [J].JAMA,1991,265(5):609-613.
-
3Burgio K L,Locher J L, Goode P S. Combined behavior al and drug therapy for urge incontinence in old women [J]. Am Geriatr Soc,2000,48(4) :37.
-
4Chess-Williams R. Muscarinic receptors of the urinary bladder= detrusor, urothelial and prejunctional[J]. Auton Autacoid Pharmacol,2002,22(3) = 133-145.
-
5Chung D E,Te A E, Staskin D R, et al. Efficacy and safety tolterodine extended release and dutasteride in nude overactive bladder patients with prostates ~ 30 grames [J]. Urology,2010,75(5) : 1144-1148.
-
6Abrams P,Swifts. Solifenacin is effective for the treat ment of OAB dry patients : pooled analysis[J]. Eur Urol,2005,48(3):483 487.
-
7Cardozo L,Hessdorfer E , Milani R , et al. Solifenacin in the treatment of urgency and other symptoms of over active bladder: results from a randomized, double blind, placebo-controlled, rising-dose trial[J]. BUJ Int, 2008, 102(9):1120-1127.
-
8Shama A,Goldberg M J, Ceninele B J. Phamacok inet ices and safety of duloxetine,a dual-seroton in and norep inephrine reuptake inhibitor [J]. Clin Phamacol, 2000,40 (2):161-167.
-
9Aoki K R. A Comparison of the safety margins of botuli- num neurotoxin serotypes A,B,and F in mice[J]. Toxi con,2001,39(12),1815-1820.
-
10Rapp D E,Lucioni A, Katz E E, et al. Use of botuli num-A tosin for the treatment of refractory overactive bladder symptoms: an initial experierce[J]. Urology, 2004,63(7):1071-1075.
二级引证文献18
-
1姜彩霞,白春颖,陈新祥,张晶,赵守庆,刘荣华.桂乌前列通颗粒治疗老年前列腺增生症的临床研究[J].智慧健康,2020,0(6):66-67.
-
2张根群.祛瘀化痰汤用于前列腺增生症治疗中的效果及作用机制探讨[J].黑龙江中医药,2020(1):68-69. 被引量：1
-
3向爱华,洪含霞.女性膀胱过度活动症的行为干预治疗及护理[J].实用临床医药杂志,2016,20(10):118-120. 被引量：4
-
4刘书航.膀胱过度活动症的临床特点及药物治疗进展[J].医学理论与实践,2018,31(5):653-654. 被引量：8
-
5王卫亚,肖尚领,翟景光.索利那新联合坦索罗辛治疗经尿道前列腺电切术后膀胱过度活动症疗效分析[J].云南医药,2018,39(5):419-421. 被引量：4
-
6鹿英强,李大勇,王丽霞,袁明殿.桑螵蛸散联合索利那新对绝经后膀胱过度活动症患者尿动力学及尿液神经生长因子的影响[J].陕西中医,2018,39(9):1228-1231. 被引量：6
-
7张国喜,白文俊.案例式教学法在泌尿外科继续医学教育中的应用[J].中国继续医学教育,2019,11(34):3-5. 被引量：7
-
8刘明祥.中西医结合治疗前列腺增生临床研究[J].医学食疗与健康,2020,18(15):34-34.
-
9纪鹏.中西医结合治疗前列腺增生合并脑血管病患者排尿功能障碍的临床研究[J].甘肃医药,2021,40(2):143-145.
-
10王荣海,王志鹏,冯润,齐湘杰.坦索罗辛联合经尿道前列腺等离子电切术治疗良性前列腺增生的临床研究[J].现代诊断与治疗,2021,32(3):364-365. 被引量：1
-
1膀胱疾病[J].国外科技资料目录（医药卫生）,2000(8):119-119.
-
2章咏裳.经尿道电切术治疗膀胱及前列腺疾病[J].临床泌尿外科杂志,2000,15(10):437-438. 被引量：116
-
3徐顺林.前列腺摘除术后膀胱痉挛处理体会[J].中国现代手术学杂志,2004,8(3):171-171.
-
4武德能.自发性膀胱破裂11例[J].广西医学院学报,1992,9(2):61-62.
-
5毕经斌,尹学军,何炜.不同浓度罗哌卡因用于经腹前列腺摘除术后硬膜外镇痛的比较[J].实用疼痛学杂志,2009(6):429-431.
-
6潘振亮,王亚非.针刺治疗膀胱过度活动症30例报告[J].山东医药,2008,48(24):84-84. 被引量：4
-
7严彬.细胞凋亡与肾脏疾病[J].医学信息（医学与计算机应用）,2002,15(1):42-43.
-
8郭德荣,牛云茜.良性前列腺增生的分子机制[J].中国老年学杂志,2000,20(5):319-320. 被引量：8
-
9周永兴.利多卡因灌注治疗前列腺摘除术后不稳定膀胱的疗效观察[J].临床泌尿外科杂志,1998,13(6):283-283. 被引量：19
-
10汪先忠,兰昊.前列腺摘除术后不稳定膀胱26例分析[J].中国误诊学杂志,2007,7(2):332-333.
